Brigitte Demers

677 total citations
15 papers, 217 citations indexed

About

Brigitte Demers is a scholar working on Molecular Biology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Brigitte Demers has authored 15 papers receiving a total of 217 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 8 papers in Oncology and 4 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Brigitte Demers's work include Cancer Research and Treatments (4 papers), Angiogenesis and VEGF in Cancer (4 papers) and PI3K/AKT/mTOR signaling in cancer (3 papers). Brigitte Demers is often cited by papers focused on Cancer Research and Treatments (4 papers), Angiogenesis and VEGF in Cancer (4 papers) and PI3K/AKT/mTOR signaling in cancer (3 papers). Brigitte Demers collaborates with scholars based in France, United States and Canada. Brigitte Demers's co-authors include Patricia Vrignaud, Marie-Christine Bissery, Pascale Lejeune, Nathalie Lassau, P. Péronneau, Serge Koscielny, Valérie Rouffiac, Estelle Bribes, Nicolas Elie and Martijn P. Lolkema and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Brigitte Demers

15 papers receiving 213 citations

Peers

Brigitte Demers

ONCOL

RNMI

Dionysis Papadatos-Pastos United Kingdom

Lintong Yao China

Lieve Adriaens United States

Junyao Xu China

Oliver Krieter Switzerland

Bouchra Tawk Germany

J. Infante United States

Thomas Cheng United States

Peter Haytko United States

Yuan Weng China

Dionysis Papadatos-Pastos United Kingdom

Brigitte Demers

136 ×1.2

99 ×1.1

ONCOL

36 ×0.7

RNMI

13 ×0.3

56 ×1.7

Citations per year, relative to Brigitte Demers Brigitte Demers (= 1×) peers Dionysis Papadatos-Pastos

Countries citing papers authored by Brigitte Demers

Since Specialization

Citations

This map shows the geographic impact of Brigitte Demers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brigitte Demers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brigitte Demers more than expected).

Fields of papers citing papers by Brigitte Demers

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brigitte Demers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brigitte Demers. The network helps show where Brigitte Demers may publish in the future.

Co-authorship network of co-authors of Brigitte Demers

This figure shows the co-authorship network connecting the top 25 collaborators of Brigitte Demers. A scholar is included among the top collaborators of Brigitte Demers based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brigitte Demers. Brigitte Demers is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Patnaik, Amita, Nilofer S. Azad, Mitesh J. Borad, et al.. (2024). An open-label phase 1 study to investigate SGNCEACAM5C/SAR445953 in adults with advanced solid tumors (SGNCEA5C-001).. Journal of Clinical Oncology. 42(16_suppl). TPS3160–TPS3160. 1 indexed citations

Pomponio, Robert J., Hong Wang, Roger Trullo, et al.. (2024). Classification of the Tumor Immune Microenvironment Using Machine-Learning-Based CD8 Immunophenotyping As a Potential Biomarker for Immunotherapy and TGF-β Blockade in Nonsmall Cell Lung Cancer. 1(2). 106–118. 3 indexed citations

Lefebvre, Anne‐Marie, Julien Adam, Céline Nicolazzi, et al.. (2023). The search for therapeutic targets in lung cancer: Preclinical and human studies of carcinoembryonic antigen-related cell adhesion molecule 5 expression and its associated molecular landscape. Lung Cancer. 184. 107356–107356. 9 indexed citations

Pomponio, Robert J., Hong Wang, Cyrus V. Hedvat, et al.. (2022). Abstract 5099: Quantification of TGFβ protein levels and digital pathology-based immune phenotyping reveal biomarkers for TGF-β blockade therapy patient selection in NSCLC. Cancer Research. 82(12_Supplement). 5099–5099. 1 indexed citations

Robbrecht, Debbie, Bernard Doger, Jean‐Jacques Grob, et al.. (2022). Safety and efficacy results from the expansion phase of the first-in-human study evaluating TGFβ inhibitor SAR439459 alone and combined with cemiplimab in adults with advanced solid tumors.. Journal of Clinical Oncology. 40(16_suppl). 2524–2524. 12 indexed citations

Stein, Anthony S., Ashish Bajel, Shaun Fleming, et al.. (2022). An Open-Label, First-in-Human, Dose-Escalation Study of SAR443579 Administered As Single Agent By Intravenous Infusion in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-Cell Acute Lymphoblastic Leukemia (B-ALL) or High-Risk Myelodysplasia (HR-MDS). Blood. 140(Supplement 1). 7476–7477. 8 indexed citations

Demers, Brigitte, et al.. (2021). 551 Pegasus Skin, a study of SAR444245 (THOR-707, a pegylated recombinant non-alpha IL2) with cemiplimab for the treatment of participants with advanced unresectable or metastatic skin cancers. SHILAP Revista de lepidopterología. A581–A581. 1 indexed citations

Weger, Vincent A. de, Maja J.A. de Jonge, Marlies H.G. Langenberg, et al.. (2018). A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours. British Journal of Cancer. 120(3). 286–293. 46 indexed citations

Bédard, Philippe L., Michael A. Davies, Scott Kopetz, et al.. (2017). First‐in‐human trial of the PI3Kβ‐selective inhibitor SAR260301 in patients with advanced solid tumors. Cancer. 124(2). 315–324. 30 indexed citations

10.

Bédard, Philippe L., Michael A. Davies, Scott Kopetz, et al.. (2015). First-in-human phase I trial of the PI3Kb-selective inhibitor SAR260301 in patients with advanced solid tumors (NCT01673737).. Journal of Clinical Oncology. 33(15_suppl). 2564–2564. 6 indexed citations

11.

Virone-Oddos, Angéla, Loı̈c Vincent, Brigitte Demers, et al.. (2013). Abstract 3258: Discovery and characterization of SAR260301, a novel PI3Kβ-selective inhibitor in clinical development for the treatment of PTEN-deficient tumors .. Cancer Research. 73(8_Supplement). 3258–3258. 4 indexed citations

12.

Conte, Gianluca Del, Rastilav Bahleda, Vı́ctor Moreno, et al.. (2012). A phase I study of ombrabulin (O) combined with bevacizumab (B) in patients with advanced solid tumors (NCT01193595).. Journal of Clinical Oncology. 30(15_suppl). 3080–3080. 11 indexed citations

13.

Lejeune, Pascale, Valérie Rouffiac, Nicolas Elie, et al.. (2008). Early Quantitative Evaluation of a Tumor Vasculature Disruptive Agent AVE8062 Using Dynamic Contrast-Enhanced Ultrasonography. Investigative Radiology. 43(2). 100–111. 73 indexed citations

14.

Lassau, Nathalie, et al.. (2007). Demonstration in animal and human of AVE8062-induced tumor blood flow shutdown using dynamic contrast enhanced-ultrasonography (DCE-US).. Cancer Research. 67. 2 indexed citations

15.

Chiron, Marielle, Patricia Vrignaud, Pascale Lejeune, et al.. (2007). Synergistic activity of aflibercept (VEGF Trap) in combination with 5-fluorouracil and irinotecan in preclinical tumor models. Molecular Cancer Therapeutics. 6. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact